How MemoHoney works: the nitric oxide chain and where it stops

This looks like duplication and it is not. Arginine taken by mouth is largely destroyed before it does anything: arginase in the intestinal wall and the liver breaks a substantial share of an oral dose down on first pass, which is why arginine supplementation has such a scattered record.

Citrulline takes a different road. It passes the liver untouched, is taken up by the kidney, and is converted there into arginine that enters the circulation directly. A 2017 study in healthy males compared citrulline, arginine and the two together on plasma arginine levels for exactly this reason.

So a formula that wants more nitric oxide substrate is right to include citrulline, and including arginine as well is defensible if there is enough of both. Whether there is, nobody outside the manufacturer knows.

Nitric oxide is a gas that diffuses across cell membranes and relaxes the smooth muscle in vessel walls. In the brain it is one of the signals behind neurovascular coupling: the mechanism that sends more blood to the region currently working, within a second or two of it starting to work.

That coupling degrades with age and with metabolic disease. A 2026 review traces nitric oxide as a mechanistic link between metabolic dysfunction and cognitive decline in type 2 diabetes, and it is a reasonable piece of biology to reason from.

Reasoning from it is not the same as testing it. The step from ‘this raises nitric oxide’ to ‘therefore this improves memory’ skips the only part a buyer cares about.

It exists, and it is the most important paper on this website.

A thirteen-week randomised trial gave overweight and obese older adults escalating doses of nitrate-rich beetroot juice and measured cognitive function and cerebral blood flow. Dietary nitrate is a more dependable route into the nitric oxide pathway than any amino acid: it does not depend on enzyme capacity, it raises plasma nitrite reliably, and it is the ingredient the sports literature actually trusts for this.

Neither cognitive function nor cerebral blood flow changed, at any dose, over three months.

One pilot trial does not close a question. It is a small study, in a specific population, with a specific compound. What it does do is put the burden of proof back where it belongs: on anyone claiming that raising nitric oxide raises cognition in people who are not deficient in anything.

The chain is real up to the second-to-last link. It is the last one that has been tested in this age group, and it did not hold.

Something completely different, and it is the reason this bottle is not simply a pre-workout with a new label.

Beta-alanine is the rate-limiting precursor of carnosine, a dipeptide that accumulates in muscle and brain tissue and acts as a pH buffer and a carbonyl scavenger. Supplementing it raises tissue carnosine over weeks rather than hours — measurably at four weeks on six grams a day.

The cognitive work is recent and small. The 2023 trial gave 2.4 grams a day for ten weeks to 100 older adults and found no whole-group effect on a screening score, but a significant improvement in the participants who started at or below normal. The 2024 imaging follow-up found structural changes in the hippocampus and amygdala in ten analysable people.

That is a thin evidence base by any standard, and it is still the strongest cognitive evidence anything on this bottle has. It is also the only mechanism here that does not run through blood vessels.

Not a mechanism. A nutrient.

Niacin is converted to NAD and NADP, the coenzymes that carry electrons through nearly every energy-producing reaction in the body, and the brain is one of the most energy-hungry organs there is. Severe deficiency produces pellagra, whose classical triad is dermatitis, diarrhoea and dementia.

That establishes that you need niacin. It does not establish that more of it helps somebody who already has enough, and in a country with a fortified food supply most people do. The Chicago Health and Aging Project is the strongest observational signal in the other direction and it measured dietary intake rather than supplements.

At the other end of the scale, high-dose niacin is a drug with real harms. HPS2-THRIVE randomised 25,673 people to extended-release niacin and found serious adverse effects and no vascular benefit. Nothing in a shared capsule approaches that dose, and the point of mentioning it is that niacin is not a vitamin to take casually in unknown amounts.

Every route here is real biology. What varies is how far along each route anyone has actually measured a cognitive outcome.